PMID- 38340923
OWN - NLM
STAT- MEDLINE
DCOM- 20240320
LR  - 20240320
IS  - 1879-0003 (Electronic)
IS  - 0141-8130 (Linking)
VI  - 262
IP  - Pt 1
DP  - 2024 Mar
TI  - Polysaccharides from Phellinus linteus attenuate type 2 diabetes mellitus in rats 
      via modulation of gut microbiota and bile acid metabolism.
PG  - 130062
LID - S0141-8130(24)00865-1 [pii]
LID - 10.1016/j.ijbiomac.2024.130062 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is the most prevalent metabolic disorder. 
      Polysaccharides from Phellinus linteus (PLP) have been found to have 
      anti-diabetes effects, but the mechanism has not been elucidated. The purpose of 
      this study was to investigate the mechanism of PLP on T2DM through the gut 
      microbiota and bile acids metabolism. The T2DM rat model was induced by a 
      high-fat high-carbohydrate (HFHC) diet and streptozocin (30 mg/kg). We found that 
      PLP ameliorated diabetes symptoms. Besides, PLP intervention increased the 
      abundance of g_Bacteroides, g_Parabacteroides, and g_Alistioes, which are 
      associated with the biosynthesis of short-chain fatty acids (SCFAs) and bile 
      acids (BAs) metabolism. Meanwhile, untargeted and targeted metabolomics indicated 
      that PLP could regulate the composition of BAs and increase the levels of SCFAs. 
      Real-time quantitative PCR (RT-qPCR) and enzyme-linked immunosorbent assay 
      (ELISA) were performed to analyze the expression levels of BAs metabolism enzymes 
      in the liver. Finally, the results of correlation analysis and Glucagon-like 
      peptide-1 (GLP-1) showed that PLP stimulated the release of GLP-1 by regulating 
      SCFAs and BAs. In conclusion, this study demonstrated that PLP can regulate gut 
      microbiota and BAs metabolism to promote GLP-1 secretion, thereby increasing 
      insulin release, decreasing blood glucose and attenuating T2DM.
CI  - Copyright (c) 2024. Published by Elsevier B.V.
FAU - Liu, Tingting
AU  - Liu T
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, 
      Shenyang, Liaoning Province, China.
FAU - Zhao, Min
AU  - Zhao M
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, 
      Shenyang, Liaoning Province, China.
FAU - Zhang, Yumeng
AU  - Zhang Y
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, 
      Shenyang, Liaoning Province, China.
FAU - Xu, Ruixiang
AU  - Xu R
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, 
      Shenyang, Liaoning Province, China.
FAU - Fu, Zixuan
AU  - Fu Z
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, 
      Shenyang, Liaoning Province, China.
FAU - Jin, Tong
AU  - Jin T
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, 
      Shenyang, Liaoning Province, China.
FAU - Song, Jiaxi
AU  - Song J
AD  - School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 
      Wenhua Road 103, Shenyang, Liaoning Province, China.
FAU - Huang, Yihe
AU  - Huang Y
AD  - School of Public Health, Shenyang Medical College, Huanghe North Street 146, 
      Shenyang, Liaoning Province, China.
FAU - Wang, Miao
AU  - Wang M
AD  - School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 
      Wenhua Road 103, Shenyang, Liaoning Province, China. Electronic address: 
      wangmiao_77111@hotmail.com.
FAU - Zhao, Chunjie
AU  - Zhao C
AD  - School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, 
      Shenyang, Liaoning Province, China. Electronic address: lab433@163.com.
LA  - eng
PT  - Journal Article
DEP - 20240208
PL  - Netherlands
TA  - Int J Biol Macromol
JT  - International journal of biological macromolecules
JID - 7909578
RN  - 0 (Polysaccharides)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 0 (Fatty Acids, Volatile)
RN  - 0 (Bile Acids and Salts)
RN  - Tropicoporus linteus
SB  - IM
MH  - Rats
MH  - Animals
MH  - *Diabetes Mellitus, Type 2/drug therapy/metabolism
MH  - *Gastrointestinal Microbiome
MH  - Polysaccharides/pharmacology/therapeutic use
MH  - Glucagon-Like Peptide 1/metabolism
MH  - Fatty Acids, Volatile
MH  - Bile Acids and Salts
MH  - *Basidiomycota
OTO - NOTNLM
OT  - Gut microbiota
OT  - Phellinus linteus polysaccharides
OT  - Type 2 diabetes mellitus
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/02/11 07:42
MHDA- 2024/03/20 06:45
CRDT- 2024/02/10 19:15
PHST- 2023/07/06 00:00 [received]
PHST- 2024/02/02 00:00 [revised]
PHST- 2024/02/06 00:00 [accepted]
PHST- 2024/03/20 06:45 [medline]
PHST- 2024/02/11 07:42 [pubmed]
PHST- 2024/02/10 19:15 [entrez]
AID - S0141-8130(24)00865-1 [pii]
AID - 10.1016/j.ijbiomac.2024.130062 [doi]
PST - ppublish
SO  - Int J Biol Macromol. 2024 Mar;262(Pt 1):130062. doi: 
      10.1016/j.ijbiomac.2024.130062. Epub 2024 Feb 8.